0001761612 false 00-0000000 true 0001761612 2022-06-27 2022-06-27 0001761612 us-gaap:CommonStockMember 2022-06-27 2022-06-27 0001761612 bcyc:AmericanDepositarySharesMember 2022-06-27 2022-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares



Washington, D.C. 20549




Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


June 27, 2022

Date of Report (Date of earliest event reported)


Bicycle Therapeutics plc

(Exact name of registrant as specified in its charter)


England and Wales   001-38916   Not applicable

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


B900, Babraham Research Campus

Cambridge CB22 3AT

United Kingdom

Not Applicable
(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: +44 1223 261503


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company    ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 5.07 Submission of Matters to a Vote of Security Holders


Bicycle Therapeutics plc (the “Company”) held its annual general meeting of shareholders (the “AGM”) on June 27, 2022. Each of the proposals set forth below were voted on and duly passed on a poll at the AGM. Detailed descriptions of these proposals and of the voting procedures applied at the AGM are contained in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2022.


There were 23,743,875 ordinary shares of the Company represented in person or by proxy at the AGM, constituting approximately 80.08% of the issued and outstanding ordinary shares on June 27, 2022. Proxy appointments which gave the Chairman of the meeting discretion have been included in the “For” total. In accordance with the terms of the deposit agreement by and among the Company, Citibank, N.A. as depositary and holders and beneficial owners of American Depositary Shares (“ADSs”) dated May 28, 2019, holders of ADSs who did not provide the depositary bank with voting instructions on or before specified deadline were deemed to have instructed the depositary bank to give a discretionary proxy to a person designated by the Company to vote the underlying ordinary shares at the AGM and the voting results below reflect that. A vote withheld/abstain is not a vote in law and is not counted in the calculation of votes for or against a resolution.


Proposal 1 - To re-elect as a director Pierre Legault.


For  Against  Vote Withheld/Abstain
22,076,711  1,442,761  2,025,261


Proposal 2 - To re-elect as a director Richard Kender.


For  Against  Vote Withheld/Abstain
23,633,473  108,372  1,802,888



Proposal 3 - To approve, on advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement.


For  Against  Vote Withheld/Abstain
23,466,799  276,755  1,801,179


Proposal 4 - To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company’s named executive officers.


1 Year  2 Year  3 Year  Vote Withheld/Abstain
16,091,884  1,483  20,845  1,803,405


Proposal 5 - To approve the amendment of the Bicycle Therapeutics plc 2020 Equity Incentive Plan to increase the number of shares available for issuance under the plan.


For  Against  Vote Withheld/Abstain
17,201,346  6,541,126  1,802,261




Proposal 6 – To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2022.


For  Against  Vote Withheld/Abstain
23,712,413  31,462  1,800,858


Proposal 7 – To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.


For  Against  Vote Withheld/Abstain
23,712,129  31,456  1,801,148


Proposal 8 - To authorize the Audit Committee to determine the Company’s U.K. statutory auditors’ remuneration for the year ending December 31, 2022.


For  Against  Vote Withheld/Abstain
23,741,689  2,158  1,800,886


Proposal 9 - To receive and adopt the Company’s U.K. statutory annual accounts and reports for the year ended December 31, 2021.


For  Against  Vote Withheld/Abstain
23,709,027  870  1,834,836



Proposal 10 - To approve the directors’ remuneration report for the year ended December 31, 2021 (excluding the directors' remuneration policy).


For  Against  Vote Withheld/Abstain
23,451,943  289,852  1,802,938






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By: /s/ Lee Kalowski
  Name: Lee Kalowski
  Title: Chief Financial Officer